Loading clinical trials...
Loading clinical trials...
A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib
Conditions
Interventions
Ceritinib
Pemetrexed
+1 more
Locations
97
United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
Memorial Cancer Institute
Hollywood, Florida, United States
Cancer Specialists of North Florida
Jacksonville, Florida, United States
University Of Miami
Miami, Florida, United States
Loyola University Medical Center
Marywood, Illinois, United States
Uni Of Iowa Hospitals And Clinics
Iowa City, Iowa, United States
Start Date
June 28, 2013
Primary Completion Date
January 26, 2016
Completion Date
November 10, 2023
Last Updated
February 7, 2025
NCT06043817
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT06476808
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions